• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Oral nicotine pouch manufacturers reduced exposure claims require evidence and regulatory oversight

Starting in 2020, several nicotine product manufacturers (eg, Puff Bar and Fre) exploited a loophole in the Tobacco Control Act (TCA) by claiming their products contained tobacco-free synthetic nicotine (SyN) and were not subject to the Food and Drug Administration’s (FDA) authority.1–3 In response, the US Congress passed a law in March 2022 expanding the TCA’s definition of ‘tobacco products’ to include products containing nicotine ‘from any source,’ including SyN. Non-therapeutic products containing SyN are subject to FDA regulation as tobacco products and must comply with all applicable regulations. As part of its enforcement against illegal nicotine products, FDA has issued warning letters to manufacturers (eg, Puff Bar in October 2022) and retailers of products purportedly containing SyN, and it has issued civil money penalties.4

FDA’s regulatory authority includes oversight of modified-risk tobacco products (MRTPs). An MRTP is defined, in part, as any…

Read the full article ›

Posted in: Journal Article Abstracts on 05/23/2024 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2025 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice